Back to Search
Start Over
Efficacy of pimobendan in the prevention of congestive heart failure or sudden death in doberman pinschers with preclinical dilated cardiomyopathy (the PROTECT study)
- Source :
- Summerfield, N J, Boswood, A, O'Grady, M R, Gordon, S G, Dukes-McEwan, J, Oyama, M A, Smith, S, Patteson, M, French, A T, Culshaw, G J, Braz-Ruivo, L, Estrada, A, O'Sullivan, M L, Loureiro, J, Willis, R & Watson, P 2012, ' Efficacy of Pimobendan in the Prevention of Congestive Heart Failure or Sudden Death in Doberman Pinschers with Preclinical Dilated Cardiomyopathy (The PROTECT Study) ', Journal of Veterinary Internal Medicine, vol. 26, no. 6, pp. 1337-49 . https://doi.org/10.1111/j.1939-1676.2012.01026.x, Summerfield, N J, Boswood, A, O'Grady, M R, Gordon, S G, Dukes-McEwan, J, Oyama, M A, Smith, S, Patteson, M, French, A T, Culshaw, G J, Braz-Ruivo, L, Estrada, A, O'Sullivan, M L, Loureiro, J, Willis, R & Watson, P 2013, ' Efficacy of Pimobendan in the prevention of congestive heart failure or sudden death in Doberman Pinschers with preclinical dilated cardiomyopathy (The PROTECT Study) ', Kleintierpraxis, vol. 58, no. 4, pp. 169-186 . https://doi.org/10.1111/j.1939-1676.2012.01026.x, Journal of Veterinary Internal Medicine
- Publication Year :
- 2012
- Publisher :
- Wiley-Blackwell, 2012.
-
Abstract
- Background: The benefit of pimobendan in delaying the progression of preclinical dilated cardiomyopathy (DCM) in Dobermans is not reported.\ud \ud Hypothesis: That chronic oral administration of pimobendan to Dobermans with preclinical DCM will delay the onset of CHF or sudden death and improve survival.\ud \ud Animals: Seventy-six client-owned Dobermans recruited at 10 centers in the UK and North America.\ud \ud Methods: The trial was a randomized, blinded, placebo-controlled, parallel group multicenter study. Dogs were allocated in a 1:1 ratio to receive pimobendan (Vetmedin capsules) or visually identical placebo.\ud \ud The composite primary endpoint was prospectively defined as either onset of CHF or sudden death. Time to death from all causes was a secondary endpoint.\ud \ud Results: The proportion of dogs reaching the primary endpoint was not significantly different between groups (P = .1). The median time to the primary endpoint (onset of CHF or sudden death) was significantly longer in the pimobendan (718 days, IQR 441–1152 days) versus the placebo group (441 days, IQR 151–641 days) (log-rank P = 0.0088). The median survival time was significantly longer in the pimobendan (623 days, IQR 491–1531 days) versus the placebo group (466 days, IQR 236–710 days) (log-rank P = .034).\ud \ud Conclusion and Clinical Importance: The administration of pimobendan to Dobermans with preclinical DCM prolongs the time to the onset of clinical signs and extends survival. Treatment of dogs in the preclinical phase of this common cardiovascular disorder with pimobendan can lead to improved outcome.
- Subjects :
- Male
Survival
evidence based medicine
Kaplan-Meier Estimate
Cardiovascular
GUIDELINES
AMBULATORY ELECTROCARDIOGRAPHY
law.invention
Death, Sudden
Clinical trials
Randomized controlled trial
law
Clinical endpoint
Dog Diseases
cardiovascular
Dilated cardiomyopathy
ASSOCIATION
musculoskeletal system
Standard Articles
Pyridazines
DOGS
cardiology
ENALAPRIL
Cardiology
cardiovascular system
Female
medicine.drug
medicine.medical_specialty
Cardiotonic Agents
Placebo
Sudden death
survival
complex mixtures
Dogs
Internal medicine
medicine
Animals
MILRINONE
cardiovascular diseases
Heart Failure
clinical trials
therapy
General Veterinary
business.industry
MORTALITY
medicine.disease
Clinical trial
Pimobendan
Heart failure
Evidence based medicine
UPDATE
Therapy
business
Subjects
Details
- Language :
- English
- ISSN :
- 08916640
- Database :
- OpenAIRE
- Journal :
- Summerfield, N J, Boswood, A, O'Grady, M R, Gordon, S G, Dukes-McEwan, J, Oyama, M A, Smith, S, Patteson, M, French, A T, Culshaw, G J, Braz-Ruivo, L, Estrada, A, O'Sullivan, M L, Loureiro, J, Willis, R & Watson, P 2012, ' Efficacy of Pimobendan in the Prevention of Congestive Heart Failure or Sudden Death in Doberman Pinschers with Preclinical Dilated Cardiomyopathy (The PROTECT Study) ', Journal of Veterinary Internal Medicine, vol. 26, no. 6, pp. 1337-49 . https://doi.org/10.1111/j.1939-1676.2012.01026.x, Summerfield, N J, Boswood, A, O'Grady, M R, Gordon, S G, Dukes-McEwan, J, Oyama, M A, Smith, S, Patteson, M, French, A T, Culshaw, G J, Braz-Ruivo, L, Estrada, A, O'Sullivan, M L, Loureiro, J, Willis, R & Watson, P 2013, ' Efficacy of Pimobendan in the prevention of congestive heart failure or sudden death in Doberman Pinschers with preclinical dilated cardiomyopathy (The PROTECT Study) ', Kleintierpraxis, vol. 58, no. 4, pp. 169-186 . https://doi.org/10.1111/j.1939-1676.2012.01026.x, Journal of Veterinary Internal Medicine
- Accession number :
- edsair.doi.dedup.....5b6c3a8b703381566cacbda4f61f2e30